Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
Launched by NOVARTIS PHARMACEUTICALS · Nov 11, 2014
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of primary Sjögren's syndrome
- • ESSDAI score ≥ 6
- Exclusion Criteria:
- • Secondary Sjögren's syndrome
- • Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimunab, other immunosuppressives.
- • At significant risk for thromboembolic event
- • Clinically significant systemic infection
- • Significant elevated risk for infection
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Basel, , Switzerland
Boston, Massachusetts, United States
Mineola, New York, United States
Debrecen, , Hungary
Duncansville, Pennsylvania, United States
Newcastle Upon Tyne, , United Kingdom
London, , United Kingdom
Edgbaston, Birmingham, United Kingdom
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials